India's Shilpa Medicare can make 100-200 million doses of COVID-19 shot, says executive

Indian drugmaker has the production capacity to make 100-200 million doses of a recombinant vaccine for COVID-19, a company executive told Reuters on Wednesday.

The company's shares jumped as much as 9.2% on India's National Stock Exchange following the news.